X4 Pharmaceuticals, Inc. XFOR
3.01
0.01
0.33%
as of 25 Sep
- Market cap
- $297.4M
- P/E
- 0.0×
Follow XFOR
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.36 | 4.82 | 57.86 | 37.23 | |
P/FCF ratio |
0.00 | 10.54 | 59.10 | 37.02 | |
P/Operating CF |
(5.32) | (10.90) | (26.61) | (28.38) | |
P/B ratio |
2.40 | 0.91 | 3.10 | 3.80 | |
Price to Tangible BV |
4.25 | 1.06 | 3.67 | 4.72 | |
EV/Sales |
3.02 | (0.19) | 40.51 | 29.00 | |
EV/EBITDA |
0.00 | 0.08 | 0.00 | 0.00 | |
EV/Operating CF |
(1.00) | 0.08 | (3.93) | (5.49) | |
EV/FCF |
(72.68) | (0.42) | 41.38 | 28.84 | |
Quick Ratio |
5.27 | 9.84 | 9.88 | 10.84 | |
Current Ratio |
5.65 | 10.16 | 10.18 | 11.30 | |
Net Debt/EBITDA |
1.69 | 7.53 | 7.83 | 8.52 | |
Debt/Assets |
46.51% | 26.27% | 28.31% | 30.33% | |
Debt/Equity |
1.23 | 0.41 | 0.45 | 0.49 | |
Asset Turnover |
0.20 | 0.16 | 0.05 | 0.09 | |
Operating CF/Net income |
0.93 | 0.65 | 0.97 | 1.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (5.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
982.27% | 721.22% | 570.53% | 171.24% | |
Selling, General and Administrative Expense of Revenue |
656.43% | 287.46% | 257.24% | 96.54% | |
Intangible Assets out of Total Assets |
0.16 | 0.09 | 0.10 | 0.12 | |
Share Based Compensation of Revenue |
43.06% | 88.43% | 89.11% | 35.04% | |
Graham Net Nets |
0.21 | 0.93 | 0.27 | 0.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(296.08%) | (108.50%) | (109.93%) | (25.70%) | |
Free Cash Flow Yield |
(0.95%) | 9.49% | 1.69% | 2.70% | |
Revenue per Share |
0.04 | 0.06 | 0.02 | 0.07 | |
Operating CF per Share |
(0.64) | (0.37) | (0.16) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.04) | |
Free Cash Flow per Share |
(0.64) | (0.37) | (0.16) | (0.20) | |
Cash per Share |
2.82 | 5.98 | 1.85 | 1.65 | |
Shareholders Equity per Share |
1.42 | 4.40 | 1.33 | 1.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.42 | 4.40 | 1.33 | 1.23 | |
Free Cash Flow |
(27.82) | (15.53) | (19.60) | (25.79) | |
Working Capital |
109.30 | 235.82 | 218.21 | 199.49 | |
Capital Expenditures |
0.00 | 0.00 | — | (5.00) | |
Net Current Asset Value |
30.87 | 157.41 | 140.15 | 121.25 | |
EV/EBIT |
0.00 | 0.08 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.57 | |
Net Profit Margin |
(1,689.24%) | (931.66%) | (747.45%) | (183.48%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.34 | 1.14 | 1.14 | 1.96 | |
Average Payables |
6.82 | 7.16 | 8.09 | 5.82 | |
Average Inventory |
3.26 | 3.65 | 3.86 | 4.34 | |
Average Assets |
170.86 | 218.45 | 200.15 | 179.12 | |
Average Common Equity |
60.62 | 104.22 | 95.70 | 79.71 |
Columns are period end dates